Europe unveils €446 million 2014-2020 health for growth programme
This article was originally published in Scrip
Officials at the European Commission have adopted proposals for the new health for growth programme which will run from 2014 to 2020. The programme, with a budget of €446 million, aims to build on previous European health programmes including promotion of more pan-European cooperation on rare diseases, health technology assessment, cancer prevention and control. The proposed programme will now go to the European Parliament and European Council of Ministers for discussion and adoption. It is anticipated that adoption will take place before the end of 2013.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.